References

1. Van Hagen P, Hulshof MCCM, Van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med*. 2012;366:2074-2084.
2. Cancer Research UK. Oesophageal cancer survival statistics; https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/survival. Accessed November 18, 2021.
3. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Cancer Stat Facts: Esophageal Cancer; https://seer.cancer.gov/statfacts/html/esoph.html. Accessed November 18, 2021.
4. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 6. Technical Supplement to Chapter 4: Searching for and selecting studies. 2019; https://training.cochrane.org/handbook/version-6/chapter-4-tech-suppl. Accessed November 18, 2021.
5. Canadian Agency for Drugs and Technologies in Health (CADTH). SR / MA / HTA / ITC - MEDLINE, Embase, PsycInfo. Last updated: December 1, 2021; https://searchfilters.cadth.ca/link/33. Accessed November 18, 2021.
6. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. *J Clin Oncol*. 2003;21:4592-4596.
7. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). *Ann Surg Oncol*. 2012;19:68-74.
8. Malaisrie SC, Hofstetter WL, Correa AM, et al. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. *Cancer*. 2006;107:967-974.
9. Jin J, Liao Z, Zhang Z, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. *Int J Radiat Oncol Biol Phys*. 2004;60:427-436.
10. Harada G, Bonadio RRCC, de Araújo FCC, et al. Induction chemotherapy for locally advanced esophageal cancer. *J Gastrointest Cancer*. 2020;51:498-505.
11. Lu SL, Hsu FM, Tsai CL, et al. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: hypothesis generating for adjuvant treatment. *Eur J Surg Oncol*. 2019;45:1498-1504.
12. Goodman KA, Ou FS, Hall NC, et al. Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) Trial. *J Clin Oncol*. 2021;39:2803-2815.
13. Ajani JA, Xiao L, Roth JA, et al. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. *Ann Oncol*. 2013;24:2844-2849.
14. Yoon DH, Jang G, Kim JH, et al. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2015;91:489-496.
15. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. *Lancet Oncol*. 2007;8:797-805.
16. Carr RA, Hsu M, Harrington CA, et al. Induction FOLFOX and PET-directed chemoradiation for locally advanced esophageal adenocarcinoma. *Ann Surg*. 2021;277:e538-e544.
17. Shimodaira Y, Slack RS, Harada K, et al. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. *Br J Cancer*. 2018;118:331-337.
18. Han J, Wang Z, Liu C. Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis. *Future Oncol*. 2021;17:2257-2274.
19. Deng HY, Wang WP, Wang YC, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. *Eur J Cardiothorac Surg*. 2017;51:421-431.
20. Fan M, Lin Y, Pan J, et al. Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. *Thorac Cancer*. 2016;7:173-181.
21. Li F, Ding N, Zhao Y, Yuan L, Mao Y. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: a systematic review and meta-analysis. *Int J Surg*. 2018;60:88-100.
22. Pasquali S, Yim G, Vohra RS, et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma. *Ann Surg*. 2017;265:481-491.
23. Huang TC, Hsu CH, Lin CC, Tu YK. Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. *Jpn J Clin Oncol*. 2015;45:1023-1028.
24. Montagnani F, Fornaro L, Frumento P, Vivaldi C, Falcone A, Fioretto L. Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: a comprehensive review and network meta-analysis. *Crit Rev Oncol Hematol*. 2017;114:24-32.
25. Reynolds JV, Preston SR, O'Neill B, et al. Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452). *J Clin Oncol*. 2021;39(15_suppl):4004.
26. Von Döbeln GA, Klevebro F, Jacobsen AB, et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: Long-term results of a randomized clinical trial. *Dis Esophagus*. 2019;32:doy078.
27. Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. *Eur J Cancer*. 2011;47:354-360.
28. Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. *Eur J Cancer*. 2017;81:183-190.
29. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol*. 2008;26:1086-1092.
30. Safran HP, Winter K, Ilson DH, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2022;23:259-269.
31. Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. *JAMA Surg*. 2021;156:721-729.
32. Engel S, Awerbuch A, Kwon D, et al. Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis. *J Gastrointest Oncol*. 2019;10:391-399.
33. Li Y, Liu H, Sun C, et al. Comparison of clinical efficacy of neoadjuvant chemoradiation therapy between lower and higher radiation doses for carcinoma of the esophagus and gastroesophageal junction: a systematic review. *Int J Radiat Oncol Biol Phys*. 2021;111:405-416.
34. Haque W, Verma V, Butler EB, Teh BS. Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base. *J Gastrointest Oncol*. 2018;9:80-89.